Exciting News! RRP is in the midst of our annual fundraising campaign, and this year, we've received a fantastic opportunity: a matching grant from a generous anonymous donor! 𝗙𝗿𝗼𝗺 𝗻𝗼𝘄 𝘂𝗻𝘁𝗶𝗹 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟯𝟭, 𝟮𝟬𝟮𝟯, 𝗥𝗥𝗣 𝘄𝗶𝗹𝗹 𝗺𝗮𝘁𝗰𝗵 𝘆𝗼𝘂𝗿

Our year end holiday celebration, love working with these enthusiastic & passionate researchers💕. We have lot to celebrate (grants, publications, promotion, lab member’s wedding ) & looking forward to have a great year ahead. Happy holidays & wonderful new year everyone🎊🌺🎉

Holiday Decorations at Peacock lane in SE Portland

Dr. LisaCoussens@CoussensLab's work “led a shift in the way we think of cancer, from a bunch of cells in isolation to considering how the surrounding microenvironment around the tumors can be exploited to develop better anti-cancer therapies.” #WomensHistoryMonth: spr.ly/6016kJt1I

Congratulations to Dr. John McClatchy Anupriya Agarwal Lab who did an amazing job yesterday in presenting highly polished seminar and defending the thesis focused on inflammation role in clonal hematopoiesis. So proud of you John 👏👏🤩 OHSU Knight Cancer Institute OHSU School of Medicine #phd

Congratulations to Dr. Mona M.Hosseini Anupriya Agarwal Lab for another beautiful thesis seminar this week with one of the shortest & smoothest defenses I have seen, focused on inflammation role in RUNX1-FPD, a rare preleukemia disorder. So proud of U Mona👏👏🤩 OHSU Knight Cancer Institute OHSU School of Medicine #phd

Yesterday was most exciting & fulfilling day of my entire scientific journey during hooding ceremony of two recent PHD graduates Dr. McClatchy & Dr. Hosseni as well as another student Dr. Lin HSIN YUN LIN came over for ceremony who missed it during Covid.OHSU School of Medicine OHSU News OHSU Knight Cancer Institute

Join our 2nd sirolimus pilot study webinar on August 9th! Dr. Courtney DiNardo (MD Anderson Cancer Center) will discuss study objectives and eligibility, and Dr. Anupriya Agarwal Lab will share the lab research that indicated sirolimus should be tested in #RUNX1FPD patients. bit.ly/tRRPSirolimusA…

Don’t miss to attend an amazing workshop #ASH24 on Germline predisposition to hematopoietic malignancies and bone marrow failure 2:00 pm Friday with great line of speakers including the work from Anupriya Agarwal Lab presented by Mona focused on RUNX1-FPD.

Happening now Mona is presenting our latest work on CD74 role in RUNX1-FPD from Anupriya Agarwal Lab in Room 7 at #ASH24 Dr. Mohan Narla, thanks to NIH NHLBI RUNX1 Research Program

Please visit OHSU Knight Cancer Institute booth at #ASH2024 in exhibit hall to Learn about multiple exciting job opportunities including Anupriya Agarwal Lab in highly collaborative environment OHSU News

Had fun catching up friends Dr. Uma Borate: Associate Professor Aditi Shastri, MD and getting glimpses of India at @Ash2024 presidential dinner, thank you ASH Dr. Mohan Narla for putting this together

If you’re at the #ASH24 conference, stop by and see us at booth 3456! 👋

Merry Christmas 🎄 And Happy Holidays to everyone from Anupriya Agarwal Lab OHSU Knight Cancer Institute. This year we got to enjoy fine cooking/baking skills at lab potluck.

Congratulations 🎊

New preprint: teaching single-cell foundation models to learn from perturbations in collaboration with Ravi Madduri & RUNX1 Research Program supported by CZI Science. Closing the loop identified a target for RUNX1-FPD now in Ph2 trials 🔗biorxiv.org/content/10.110… 🧵by @yash_persh👇

A new preprint led by Alex Bick, Ravi Madduri, and Yash Pershad, with co-authors including Anupriya Agarwal Lab and RRP’s Katrin Ericson, uses a closed-loop #AI system to identify and validate therapeutic targets for RUNX1-FPD. One of these targets, mTOR, supports earlier findings by